From: In silico drug repositioning based on integrated drug targets and canonical correlation analysis
Drug name | Disease name | Ranking in the prediction list | Evidence |
---|---|---|---|
Troglitazone | Hypertriglyceridemia | Top 1 | CTD |
Methysergide | Migraine disorders | Top 1 | CTD |
Ropivacaine | Pruritus | Top 1 | CTD |
Tenofovir disoproxil | HIV infections | Top 1 | CTD |
Remoxipride | Schizophrenia | Top 1 | CTD |
Rosiglitazone | Hypercholesterolemia | Top 1 | CTD |
Cerivastatin | Hypercholesterolemia | Top 1 | CTD |
Meperidine | Pain | Top 1 | CTD |
Dronabinol | Obesity | Top 1 | CTD |
Phenindione | Thromboembolism | Top 1 | CTD |
Amodiaquine | Malaria, falciparum | Top 1 | CTD |
Alfentanil | Pain | Top 1 | CTD |
Risedronic acid | Osteoporosis, postmenopausal | Top 1 | CTD |
Levobupivacaine | Pruritus | Top 1 | CTD |
Ketamine | Pain | Top 1 | CTD |
Sulfadoxine | Malaria, falciparum | Top 1 | CTD |
Methotrimeprazine | Schizophrenia | Top 1 | CTD |
Acenocoumarol | Thromboembolism | Top 1 | CTD |
Diamorphine | Pain | Top 1 | CTD |
Pimavanserin | Schizophrenia | Top 1 | CTD |
Ciprofibrate | Hypertriglyceridemia | Top 1 | CTD |
Vitamin d | Hypoparathyroidism | Top 1 | CTD |
Elagolix | Endometriosis | Top 1 | CTD |
mg132 | Multiple myeloma | Top 1 | CTD |